Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.
♦ BACKGROUND: Peritonitis is a major problem among patients on peritoneal dialysis (PD). The influence of diverse PD fluids on the activity of frequently used antibiotics has been insufficiently investigated. Thus, the present study set out to investigate the impact of different PD fluids on the activity of cefepime, ciprofloxacin, ertapenem, meropenem, and tobramycin against Escherichia coli. ♦ METHODS: Time-kill curves in 4 different PD fluids (Dianeal PDG4, Extraneal, Nutrineal PD4 and Physioneal 40, all Baxter Healthcare Corp., Deerfield, IL, USA) were performed over 24 hours with 4 different concentrations (1 × minimum inhibitory concentration [MIC], 4 × MIC, 8 × MIC, 30 × MIC) of each antibiotic evaluated and without antibiotics as control. Cation-adjusted Mueller Hinton broth (CA-MHB) was used as comparator solution. ♦ RESULTS: In all PD fluids investigated, bacterial growth and antimicrobial activity of all antibiotics tested was significantly reduced compared with the CA-MHB comparator solution. Except at high concentrations of 30 × MIC, cefepime, ertapenem and meropenem demonstrated a strongly reduced activity in all PD fluids investigated. Ciprofloxacin and tobramycin were highly active and bactericidal in all PD fluids and demonstrated dose-dependent activity. ♦ CONCLUSION: The antimicrobial activity of cefepime, ertapenem and meropenem is limited or even nullified in certain PD fluids in vitro, whereas ciprofloxacin and tobramycin show excellent activity. The choice of PD fluids can impact the activity of antimicrobial agents and might influence microbiological outcome. Further studies are required to verify the clinical relevance of our findings.
Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Vienna, Austria.
Manuel
M
Kussmann
Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Vienna, Austria.
Linda
L
Schuster
Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Vienna, Austria.
Sarah
S
Wrenger
Department of Internal Medicine I, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, St. Poelten, Austria.
Petra
P
Pichler
Department of Pharmacognosy, University of Vienna, Vienna, Austria.
Gottfried
G
Reznicek
Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Vienna, Austria.
Heinz
H
Burgmann
Department of Internal Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University Vienna, Vienna, Austria.|Department of Dermatology, Medical University of Vienna, Austria.
Wolfgang
W
Poeppl
Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria markus.zeitlinger@meduniwien.ac.at.
Markus
M
Zeitlinger
Department of Internal Medicine I, University Hospital St. Poelten, Karl Landsteiner University of Health Sciences, St. Poelten, Austria.
Martin
M
Wiesholzer
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000077723:Cefepime; D002511:Cephalosporins / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D015314:Dialysis Solutions / Q000009:adverse effects / Q000494:pharmacology*; D000077727:Ertapenem; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D066298:In Vitro Techniques; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D010530:Peritoneal Dialysis / Q000009:adverse effects* / Q000379:methods; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology; D012680:Sensitivity and Specificity; D013845:Thienamycins / Q000494:pharmacology; D014031:Tobramycin / Q000494:pharmacology; D047090:beta-Lactams / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D015314:Dialysis Solutions; D013845:Thienamycins; D047090:beta-Lactams; D002939:Ciprofloxacin; D000077723:Cefepime; D000077731:Meropenem; D000077727:Ertapenem; D014031:Tobramycin
Antibiotics; infection; peritoneal dialysis solutions; peritonitis; time-kill curves
Perit Dial Int. 2014 Mar-Apr;34(2):162-70
24584620
Perit Dial Int. 2010 Mar-Apr;30(2):250-1
20200373
Perit Dial Int. 2013 Nov-Dec;33(6):708-9
24335130
Perit Dial Int. 1995 Oct-Dec;15(8):328-35
8785230
Perit Dial Int. 2011 Nov-Dec;31(6):688-92
22123854
J Gen Microbiol. 1986 May;132(5):1297-304
3534137
Adv Perit Dial. 2004;20:74-7
15384800
Clin Nephrol. 2011 May;75(5):416-25
21543021
Perit Dial Int. 2002 May-Jun;22(3):339-44
12227391
Eur J Clin Microbiol. 1983 Apr;2(2):111-5
6222896
Perit Dial Int. 2010 Jul-Aug;30(4):393-423
20628102
Antimicrob Agents Chemother. 2003 Dec;47(12):3764-7
14638479
Clin Infect Dis. 1998 Jul;27(1):10-22
9675443
Antimicrob Agents Chemother. 1985 Oct;28(4):524-7
2934022
Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1327-34
22009289
Am J Hosp Pharm. 1992 Dec;49(12):2956-9
1481801
Antimicrob Agents Chemother. 1985 Jun;27(6):908-11
3927837
Cochrane Database Syst Rev. 2014 Apr 26;(4):CD005284
24771351
World J Nephrol. 2015 May 6;4(2):287-94
25949943
Perit Dial Int. 2005 Jul-Aug;25(4):380-6
16022096
Antimicrob Agents Chemother. 1987 Apr;31(4):657-9
3606070
Eur J Clin Microbiol Infect Dis. 2015 Nov;34(11):2257-63
26337433
Perit Dial Int. 2004 Sep-Oct;24(5):433-9
15490982
Clin Infect Dis. 1998 Jul;27(1):23-7
9675444
Perit Dial Int. 2009 Jan-Feb;29(1):52-7
19164253
Perit Dial Int. 1995 Jul-Sep;15(6):283-4
7578517
Clin Microbiol Rev. 1988 Jan;1(1):54-9
3060245
Pharmacology. 2012;90(5-6):281-7
23037005
Antimicrob Agents Chemother. 1986 May;29(5):797-802
3089141
Antimicrob Agents Chemother. 2012 Feb;56(2):725-30
22083473
Perit Dial Int. 2004 Nov-Dec;24(6):590-5
15559489